ITOS (iteostherapeutics.com) Enterprise Value-to-Revenue Coefficient

iTeos Therapeutics Inc (ITOS) - corporate logo

Strong financial discipline from iTeos Therapeutics (ITOS) management and liquidity from GSK create a solid foundation, yet dependence on an R&D partner and the risks of clinical failures render the EV/Sales ratio volatile. The mark captures this metric, visualizing the business value excluding debt. The ultimate attractiveness of the asset is determined by future royalties from the commercialization of cancer immunotherapies.

iTeos Therapeutics, Inc. (ITOS): Enterprise Value-to-Revenue Ratio from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for iTeos (ITOS)

- market price and analyst price targets:
- business market valuation indicators:
Fundamental valuation:iTeos Therapeutics (ITOS)
Original product of iTeos Therapeutics Inc

As iTeos Therapeutics (ITOS) engages in a fierce battle with biotech giants for leadership in immuno-oncology, any shifts in the market potential of its drugs immediately impact its capitalization. This enterprise value-to-revenue ratio, which excludes the influence of debt, measures the premium the market is willing to pay per unit of sales, allowing investors to determine whether the asset is undervalued or overvalued relative to its fundamentals.

Competitor analysis for iTeos Therapeutics

ARGX - EV/Sales Multiple|BNTX: EV/Sales Multiple|ABVX (Abivax SA) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ADMA Corp|Enterprise Value-to-Revenue Multiple Protagonist Therapeutics PTGX|Company Value to Revenue IMVT (Immunovant Therapeutics)|Total Company Value-to-Revenue Ratio kiniksa.com|Enterprise Value-to-Revenue Ratio Grifols Biemat GRFS|Enterprise Value-to-Revenue Coefficient ADPT (Adaptive Biotechnologies Corporation)|celldex.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Aurinia Pharma AUPH|biocryst.com (BCRX) - Enterprise Value-to-Revenue Ratio|Vera Therapeutics, Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Dianthus Therapeutics Inc|Pharvaris NV (PHVS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple ABCL|Tourmaline Corp - Company Value to Revenue Ratio|EV/Sales Multiple PGEN (precigen.com)|Enterprise Value-to-Sales Ratio pharming.com|NKTR - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Upstream Bio Corp|ZBIO: EV/Sales Multiple|Company Value to Revenue Immunome, Inc.|Company Value to Revenue GOSS|KALV: Business Value to Revenue|EV/Sales Multiple SEPN|Company Value to Revenue Pieris Pharmaceuticals, Inc. PVLA|EV/Sales Multiple SVRA (Savara Inc)|EV/Sales Multiple Rigel Pharmaceuticals RIGL|AnaptysBio Inc. - EV/Sales Multiple|Astria Therapeutics - Enterprise Value-to-Revenue Coefficient|ENGN: EV/Sales Multiple|RAPT - Total Company Value-to-Revenue Ratio|Company Value to Revenue JBIO|Aclaris (ACRS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple KYTX|Company Value to Revenue Tiziana Life Sciences TLSA|EV/Sales Multiple CABA (cabalettabio.com)|Enterprise Value-to-Revenue Coefficient VTYX (Ventyx Bio)|Theratechnologies, Inc - EV/Sales Multiple|AVTX (Avalo Therapeutics Inc.) - Company Value to Revenue Ratio|eledon.com (ELDN) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio AGEN|CLYM (climbbio.com) - EV/Sales Multiple|EV/Sales Multiple zurabio.com|Enterprise Value-to-Revenue Ratio aTyr (ATYR)|ADAG - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio ImageneBio Inc IMA|EV/Sales Multiple Shattuck Labs, Inc. STTK|EQ - Enterprise Value-to-Revenue Ratio|connectbiopharm.com (CNTB) - Company Value to Revenue|IMUX (Immunic) - Company Value to Revenue|Atara Biotherapeutics, Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio InflaRx|Company Value to Revenue x4pharma.com (XFOR)|EV/Sales Multiple ACET|Company Value to Revenue Celularity Corp CELU|INmune Bio Inc - Company Value to Revenue|BRNS (Barinthus Bio) - Enterprise Value to Sales Volume|KZR - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio sabbiotherapeutics.com SABS|Akari Therapeutics PLC (AKTX) - Enterprise Value-to-Revenue Ratio|ENLV - Total Company Value-to-Revenue Ratio|QTTB (Q32 Bio) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple GeoVax Labs Inc GOVX|Enterprise Value-to-Revenue Ratio Edesa Biotech (EDSA)|Company Value to Revenue iBio IBIO|Carisma Therapeutics Inc - Company Value to Revenue|XTLB - Company Value to Revenue|BOLT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue HCWB (hcwbiologics.com)|APVO: EV/Sales Multiple|aimimmuno.com (AIM) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio aditxt.com|Company Value to Revenue GRI Bio Corp (GRI)|Enterprise Value-to-Revenue Ratio XORTX Therapeutics Inc. (XRTX)|Company Value to Revenue ReShape Lifesciences HIND|Enterprise Value-to-Revenue Ratio Revelation Biosciences REVB|INDP: Company Value to Revenue Ratio|SCNI - Enterprise Value-to-Revenue Ratio|CALI (calcimedica.com) - Company Value to Revenue Ratio|AFMD (Affimed Therapeutics) - Company Value to Revenue|Allakos Therapeutics (ALLK) - EV/Sales Multiple|HOOK (HOOKIPA) - EV/Sales Multiple|igmbio.com (IGMS) - Total Company Value-to-Revenue Ratio|Company Value to Revenue OCEA (Ocean Biomedical)|TCBP: Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Third Harmonic Bio Inc THRD